Trial Profile
A Phase 1 Dose Escalation Trial of Ipilimumab in Combination With CG1940 and CG8711 in Patients With Metastatic Hormone-Refractory Prostate Cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Tumour cell vaccine-GVAX (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 05 Mar 2012 Results were published in The Lancet Oncology (February 2012) journal, according to a BioSante Pharmaceuticals media release
- 19 Jan 2012 Status changed from active, no longer recruiting to discontinued.
- 03 Jun 2008 Interim results reported at the American Society of Clinical Oncology annual meeting 2008.